180 related articles for article (PubMed ID: 17407229)
1. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
Singh G; Saxena N; Aggarwal A; Misra R
J Rheumatol; 2007 Apr; 34(4):731-3. PubMed ID: 17407229
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
Mok CC; Lau CS; Wong RW
Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus.
Ngamjanyaporn P; Thakkinstian A; Verasertniyom O; Chatchaipun P; Vanichapuntu M; Nantiruj K; Totemchokchyakarn K; Attia J; Janwityanujit S
Rheumatol Int; 2011 Sep; 31(9):1215-8. PubMed ID: 20358205
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.
Winoto J; Song H; Hines C; Nagaraja H; Rovin BH
Clin Nephrol; 2011 May; 75(5):451-7. PubMed ID: 21543025
[TBL] [Abstract][Full Text] [Related]
6. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
[TBL] [Abstract][Full Text] [Related]
7. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
8. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
Mok CC; Chan PT; To CH
Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand.
Akawatcharangura P; Taechakraichana N; Osiri M
Lupus; 2016 Apr; 25(4):436-44. PubMed ID: 26621134
[TBL] [Abstract][Full Text] [Related]
10. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
Laskari K; Zintzaras E; Tzioufas AG
Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide boluses induce micronuclei expression in buccal mucosa cells of patients with systemic lupus erythematosus independent of cytochrome P450 2D6 status.
Aceves Avila FJ; Esquivel Nava GA; Gallegos Arreola MP; Gómez Meda B; Zúñiga González G; Ramos-Remus C
J Rheumatol; 2004 Jul; 31(7):1335-9. PubMed ID: 15229952
[TBL] [Abstract][Full Text] [Related]
12. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.
Katsifis GE; Tzioufas AG
Lupus; 2004; 13(9):673-8. PubMed ID: 15485101
[TBL] [Abstract][Full Text] [Related]
13. Ovarian Insufficiency is Major Short-term Toxicity in Systemic Lupus Erythematosus Patients Treated with Cyclophosphamide.
Singh G; Misra R; Aggarwal A
J Assoc Physicians India; 2016 Feb; 64(2):28-31. PubMed ID: 27730777
[TBL] [Abstract][Full Text] [Related]
14. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
15. Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.
Shu W; Guan S; Yang X; Liang L; Li J; Chen Z; Zhang Y; Chen L; Wang X; Huang M
Br J Clin Pharmacol; 2016 Feb; 81(2):327-40. PubMed ID: 26456622
[TBL] [Abstract][Full Text] [Related]
16. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
[TBL] [Abstract][Full Text] [Related]
18. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.
Kortunay S; Bozkurt A; Bathum L; Basci NE; Calgüneri M; Brøsen K; Kayaalp SO
Ann Rheum Dis; 1999 Mar; 58(3):182-5. PubMed ID: 10364917
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
